Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics

Int Urol Nephrol. 2022 Jun;54(6):1215-1223. doi: 10.1007/s11255-022-03175-8. Epub 2022 Mar 16.

Abstract

Purpose: Treatment of voiding dysfunction due to detrusor underactivity (DU) remains challenging. This study sought to determine the characteristics of video urodynamic study (VUDS) in female DU and outcomes after active treatment.

Methods: A total of 409 female patients with VUDS-proven DU were recruited. All patients received conservative bladder management, with others receiving active treatment, such as oral medication, transurethral incision of bladder neck (TUI-BN), surgery for prolapse, and urethral botulinum toxin A (BoNT-A) injection, according to their VUDS characteristics. Treatment outcomes were then analyzed by different VUDS characteristics.

Results: Satisfactory treatment outcomes were noted in 123 patients (30.0%), among whom 35 and 88 had a VE of > 90% and > 66.7%, respectively. A total of 165 patients (40.3%) had voiding efficiency (VE) of 33.3-66.7%, whereas 121 (29.6%) remained unable to void (12.5%) or had a VE of < 33.3% (17.1%). Conservative treatment had the worst outcome. Patients with normal or slightly reduced bladder sensation (49.3%) and those with a post-void residual (PVR) of < 250 mL (59.4%) displayed better satisfactory outcome after treatment; while TUI-BN and urethral BoNT-A injection promoted better treatment results. Patients with detrusor acontractility and a PVR of ≥ 500 mL still achieved high VE rates (> 66.7%) after TUI-BN. A 56.3% satisfactory outcome was achieved after TUI-BN, whereas 58.1% satisfactory outcome was noted in those with a tight external sphincter after medical treatment.

Conclusion: Female patients with DU exhibited VE improvement after active treatment. Patients with very low detrusor contractility and absent bladder sensation generally exhibited poor treatment outcomes.

Keywords: Detrusor; Surgical treatment; Urinary retention; Urodynamics.

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Female
  • Humans
  • Male
  • Retrospective Studies
  • Treatment Outcome
  • Urethra
  • Urinary Bladder, Underactive* / complications
  • Urinary Bladder, Underactive* / therapy
  • Urodynamics

Substances

  • Botulinum Toxins, Type A